EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy

Shuxin Peng iD, Jiangpeng Wu, Shasha Wang, Ying Gao, Xuran Guo, Mengpan Li iD, Youjin Wu, Yun Wang, Zhengdong Cai iD, Yingqi Hua iD, Peng Wei iD, Yinghua Gao iD und 1 weitere

Smart Molecules · 03.08.2026

DOI: 10.1002/smo2.70084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Smart Molecules, online erschienen am 03.08.2026. Verfasst von Shuxin Peng und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Fiber Materials College of Chemistry and Chemical Engineering Donghua University Shanghai China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MYC‐amplified osteosarcoma, a poor‐prognosis molecular subtype, presents formidable therapeutic challenges due to its aggressive phenotype, chemoresistance, and the “undruggable” oncogenic driver MYC. A single‐molecule prodrug, DHU‐NO3, was developed to achieve precise synergy between photodynamic therapy (PDT) and nitric oxide (NO) gas therapy for the treatment of MYC‐amplified osteosarcoma. This prodrug covalently links the clinically approved photosensitizer methylene blue (MB) to an NO donor and undergoes a sequential activation cascade: reactive oxygen species‐triggered MB release, 405 nm light‐controlled NO generation, and PDT initiation under 650 nm laser irradiation. In 143B osteosarcoma cells, this temporally coordinated regimen efficiently induces apoptosis and potently suppresses the MYC signaling network. In the 143B osteosarcoma subcutaneous xenograft model, DHU‐NO3‐mediated sequential phototherapy demonstrated robust tumor growth inhibition with favorable biosafety. This work establishes a spatiotemporally programmable prodrug platform and provides a potent strategy to combat MYC‐amplified osteosarcoma by indirect pathway suppression.

Schlagwörter

Stichwörter der Autor:innen

MYCnitric oxideosteosarcomaphotodynamic therapyprodrug

Autor:innen und Institutionen

  • State Key Laboratory of Advanced Fiber Materials College of Chemistry and Chemical Engineering Donghua University Shanghai China.
  • Department of Orthopedic Oncology Shanghai Bone Tumor Institute Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Department of Orthopaedics Jinshan Hospital Fudan University Shanghai China.

ORCID-Profile: Shuxin Peng, Mengpan Li, Zhengdong Cai, Yingqi Hua, Peng Wei, Yinghua Gao, Tao Yi

Zitieren

APA

Peng, S., Wu, J., Wang, S., Gao, Y., Guo, X., Li, M., Wu, Y., Wang, Y., Cai, Z., Hua, Y., Wei, P., Gao, Y., & Yi, T. (2026). A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy. Smart Molecules. https://doi.org/10.1002/smo2.70084

Vancouver

Peng S, Wu J, Wang S, Gao Y, Guo X, Li M, et al. A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy. Smart Molecules. 2026. doi:10.1002/smo2.70084

BibTeX
@article{Peng2026,
  author = {Peng, Shuxin and Wu, Jiangpeng and Wang, Shasha and Gao, Ying and Guo, Xuran and Li, Mengpan and Wu, Youjin and Wang, Yun and Cai, Zhengdong and Hua, Yingqi and Wei, Peng and Gao, Yinghua and Yi, Tao},
  title = {A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy},
  journal = {Smart Molecules},
  year = {2026},
  doi = {10.1002/smo2.70084}
}
Kostenlos starten →